SMMT
Closed
Summit Therapeutics Plc
21.2
-0.1 (-0.47%)
Last Update: 01 Jul 2025 23:00:00
Yesterday: 21.28
Day's Range: 20.6207 - 21.76
Send
sign up or login to leave a comment!
When Written:
1.605
Summit Therapeutics PLC is a biopharmaceutical company that focuses on developing treatments for rare diseases. The company is headquartered in Oxford, United Kingdom, and has a subsidiary in Cambridge, Massachusetts, USA.
Summit Therapeutics is primarily focused on developing treatments for muscle-wasting diseases, such as Duchenne muscular dystrophy and Charcot-Marie-Tooth disease. The company's lead product candidate is ezutromid, which is being developed for the treatment of Duchenne muscular dystrophy.
In addition to ezutromid, Summit Therapeutics is also developing a pipeline of other product candidates, including treatments for C. difficile infection and rare genetic diseases.
The company was founded in 2003 and went public on the NASDAQ stock exchange in 2015. As of 2021, Summit Therapeutics has a market capitalization of approximately $70 million.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
Summit Therapeutics is primarily focused on developing treatments for muscle-wasting diseases, such as Duchenne muscular dystrophy and Charcot-Marie-Tooth disease. The company's lead product candidate is ezutromid, which is being developed for the treatment of Duchenne muscular dystrophy.
In addition to ezutromid, Summit Therapeutics is also developing a pipeline of other product candidates, including treatments for C. difficile infection and rare genetic diseases.
The company was founded in 2003 and went public on the NASDAQ stock exchange in 2015. As of 2021, Summit Therapeutics has a market capitalization of approximately $70 million.
Note: This message is generated by artificial intelligence; it does not guarantee the accuracy of the information it contains and should not be considered as investment advice.
(0)
(0)
Send
sign up or login to leave a comment!!








